Who Paid My Doc
Andexxa
Biological Rare Disease
NDC 69853-0102-1
General payments
$5,164,329
Research payments
$5,379,295
Through program year 2025, $5,164,329 in general payments and $5,379,295 in research payments were reported against Andexxa (Rare Disease).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
7 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | General | $19,057 | 129 |
| 2025 | Research | $2,748,564 | 102 |
| 2024 | General | $1,239,600 | 8,014 |
| 2024 | Research | $2,517,507 | 78 |
| 2023 | General | $2,022,299 | 9,874 |
| 2023 | Research | $113,224 | 1 |
| 2022 | General | $1,883,373 | 8,070 |
Breakdown
The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.
The top 5 of 16 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.
The top 5 of 7 states; each share is of general payments naming this product in 2025 where a state was reported.
Records
26,087 general · 181 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.